drugset / Trial / NCT03311412
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to see if Sym021 is safe and tolerable as monotherapy, in combination with either Sym022 or Sym023, and in Combination with both Sym022 and Sym023 for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Timeline
- Start
- 2017-11-20
- Primary completion
- 2022-03-23
- Completion
- 2022-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sym021 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Sym022 | Unknown | 1 mg/kg | Intravenous |
| Subject | Sym022 | Unknown | 3 mg/kg | Intravenous |
| Subject | Sym022 | Unknown | 5 mg/kg | Intravenous |
| Subject | Sym023 | Monoclonal antibody | — | Intravenous |